



Bioactive compounds from *Physalis angulata* and their anti-inflammatory and cytotoxic activities

Hoang Le Tuan Anh , Vinh Le Ba , Thi Thao Do , Van Kiem Phan , Hai Yen Pham Thi , Long Giang Bach , Manh Hung Tran , Phuong Anh Tran Thi & Young Ho Kim

To cite this article: Hoang Le Tuan Anh , Vinh Le Ba , Thi Thao Do , Van Kiem Phan , Hai Yen Pham Thi , Long Giang Bach , Manh Hung Tran , Phuong Anh Tran Thi & Young Ho Kim (2020): Bioactive compounds from *Physalis angulata* and their anti-inflammatory and cytotoxic activities, Journal of Asian Natural Products Research, DOI: [10.1080/10286020.2020.1825390](https://doi.org/10.1080/10286020.2020.1825390)

To link to this article: <https://doi.org/10.1080/10286020.2020.1825390>

 View supplementary material 

 Published online: 08 Oct 2020.

 Submit your article to this journal 

 View related articles 

 View Crossmark data 



Bioactive compounds from *Physalis angulata* and their anti-inflammatory and cytotoxic activities

Hoang Le Tuan Anh^{a,b*}, Vinh Le Ba^{c,d*}, Thi Thao Do^{b,e}, Van Kiem Phan^c,
Hai Yen Pham Thi^b, Long Giang Bach^f, Manh Hung Tran^g,
Phuong Anh Tran Thi^b and Young Ho Kim^d 

^aMientrung Institute for Scientific Research, Vietnam Academy of Science and Technology, 321 Huynh Thuc Khang, Hue City, Thua Thien Hue 531600, Vietnam; ^bGraduated University of Science and Technology, Vietnam Academy of Science and Technology, Ha Noi 10307, Vietnam; ^cInstitute of Marine Biochemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Ha Noi 10307, Vietnam; ^dCollege of Pharmacy, Chungnam National University, Daejeon 34134, Korea; ^eInstitute of Biotechnology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Ha Noi 10307, Vietnam; ^fNguyen Tat Thanh University, 300A Nguyen Tat Thanh, Ho Chi Minh City 748000, Vietnam; ^gMedicinal Chemistry Division, Faculty of Chemistry, University of Science, Vietnam National University Hochiminh city, 227 Nguyen Van Cu, Ho Chi Minh City 748000, Vietnam

ABSTRACT


A new compound, physalucoside A (1), together with seven withanolides (2–8) and three flavonoids (9–11), were isolated from *Physalis angulata* L. (Solanaceae), a medicinal plant native to Vietnam. The chemical structures of these compounds were elucidated by one- and two-dimensional NMR spectra, high-resolution electrospray ionization mass spectrometry analyses, and chemical reactivity. The anti-inflammatory and cytotoxic activities of isolated compounds were also evaluated. These data suggest that the anti-inflammatory activity of *P. angulata* is due primarily to its withanolide content. This study demonstrates the potential of withanolides as promising candidates for the development of new anti-inflammatory drugs.

ARTICLE HISTORY

Received 26 June 2019
Accepted 16 September 2020

KEYWORDS

Physalis angulata;
solanaceae; physalucoside A; withanolides; anti-inflammatory; cytotoxic activity



CONTACT Young Ho Kim  yhk@cnu.ac.kr  College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; Hoang Le Tuan Anh  hoangletuananh@hotmail.com  Mientrung Institute for Scientific Research, Vietnam Academy of Science and Technology, 321 Huynh Thuc Khang, Hue City, Thua Thien Hue 531600, Vietnam

*These authors contributed equally to this work.

 Supplemental data for this article is available online at <https://doi.org/10.1080/10286020.2020.1825390>.

1. Introduction

Inflammatory diseases and disorders include autoimmune diseases, cancers, metabolic syndromes, and cardiovascular diseases. Diverse pro-inflammatory cytokines and mediators, such as interleukin 1β , tumor necrosis factor α , interleukin 6, prostaglandins, and nitric oxide (NO), are released mainly by activated macrophages [1] in response to exogenous stress or endogenous signals including external pathogens and damage-associated molecular patterns [2]. The inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) plays an important role in many inflammatory disease therapies. Hence, selective iNOS and COX-2 inhibitors are potential candidates for new therapeutic agents against inflammation.

The plant *Physalis angulata* L. belongs to the genus *Physalis* (Solanaceae), which includes approximately 120 species distributed primarily within South and North America, with a few species found in Europe and southeastern and central Asia [3]. In Vietnam, four species of *Physalis* are identified with the local name Tam Bop [4]. It is used widely in Vietnamese folk medicines for treating fever, cough, vomiting, hiccups, and diabetes. *Physalis* fruit is eaten in China, Korea, Japan, and Vietnam for its high levels of vitamin C, vitamin B1, and pro-vitamin A [5]. The fruits are also used to prevent urinary tract infections, kidney inflammation, and gout. Interestingly, the branches, fruits, or leaves of *P. angulata* are used as one of the ingredients in a traditional anti-cancer (cervical, throat, lung, and colon) medicine that also includes *Atractylodes macrocephala*, *Platycodon grandiflorus*, *Ophiopogon japonicus*, *Scrophularia buergeriana*, *Scutellaria baicalensis*, and *Glycyrrhiza uralensis* [4]. As with other *Physalis* sp., *P. angulata* produces withanolide triterpenoids containing a steroidal lactone possessing 28 carbon atoms [6,7]. These compounds have exhibited antimicrobial, anticancer, anti-inflammatory, hepatoprotective, immunomodulatory, and insect-repelling properties [8–11].

In our anti-inflammatory screening program evaluating Vietnamese medicinal and natural plants, an ethanol extract of *P. angulata* exhibited significant inhibition of NO production. This report describes the isolation and structural elucidation of a new alkaloid, physalucoside A (1), from the branches of *P. angulata*, along with 10 known compounds comprising withanolides (2–8) and flavonoids (9–11). The anti-inflammatory and cytotoxic activities of these compounds were also investigated. Moreover, their effects on protein expression were determined by Western blot analysis.

2. Results and discussion

Bioassay-guided separation of the MeOH extract of *P. angulata* resulted in the isolation and structural elucidation of eleven compounds (1–11) (Scheme S1, and Extraction and isolation), including new compound 1. The known compounds were identified as physagulin B (2), (20*S*,22*R*)-15 α -acetoxy-5 α -chloro-6 β ,14 β -dihydroxy-1-oxowitha-2,24-dienonide (3), physalin F (4), physalin B (5), physalin G (6), and physagulide Q (7), physagulin D (8) [6,12–15], and three flavonoid glucosides as quercetin 3-*O*- β -rutinoside (9), kaempferol 3-*O*- β -rutinoside (10), and kaempferol 3-*O*- β -rutinoside-7-*O*- β -D-glucopyranoside (11) [16] by comparison of their NMR spectroscopic data to those previously reported values.

Table 1. ^1H and ^{13}C NMR spectral data of new compound **1**.

No.	$\delta_{\text{C}}^{\text{a,b}}$	$\delta_{\text{H}}^{\text{a,c}}$ (mult., J in Hz)
1	128.0	–
2	111.7	7.03 (d, $J = 1.5$ Hz)
3	149.3	–
4	149.9	–
5	116.5	6.69 (d, $J = 8.5$ Hz)
6	123.3	6.93 (dd, $J = 1.5, 8.5$ Hz)
7	142.4	7.34 (d, $J = 15.5$ Hz)
8	118.6	6.32 (d, $J = 15.5$ Hz)
9	169.3	–
1'	132.3	–
2'	129.2	7.15 (d, $J = 8.5$ Hz)
3'	115.9	6.65 (d, $J = 8.5$ Hz)
4'	158.2	–
5'	115.9	6.65 (d, $J = 8.5$ Hz)
6'	129.2	7.15 (d, $J = 8.5$ Hz)
7'	81.8	4.75–4.77 (m)*
8'	47.7	3.46 (dd, $J = 7.0, 13.5$ Hz) 3.63 (ddd, $J = 5.5, 13.5$ Hz)
3-OMe	56.4	3.79 (s)
1''	104.5	4.40 (d, $J = 7.5$ Hz)
2''	75.5	3.20–3.22 (m)
3''	78.1	3.25 (d, $J = 9.0$ Hz)
4''	71.5	3.18 (dd, $J = 5.0, 9.0$ Hz)
5''	77.9	3.09 (dd, $J = 2.5, 5.5$ Hz)
6''	62.6	3.46–3.48 (m)/3.60–3.62 (m)

^aMeasured in CD_3OD .^b125 MHz.^c500 MHz.

*This assignment may be interchanged.

Compound **1** was obtained as a white amorphous powder and showed a positive reaction with Dragendorff's reagent. The molecular formula of **1** was $\text{C}_{24}\text{H}_{29}\text{NO}_{10}$, based on positive-mode high-resolution electrospray ionization mass spectrometry, which yielded a protonated molecular ion at m/z 492.1838 $[\text{M} + \text{H}]^+$. Infrared absorption spectrum indicated the presence of hydroxyl (3380 cm^{-1}), carboxylic acid (1635 cm^{-1}), and aromatic ring ($1,60,51,520\text{ cm}^{-1}$) moieties. The ^1H -NMR spectrum of **1** indicated the presence of an ABX proton system with peaks at δ 7.03 (1H, d, $J = 1.5$ Hz, H-2), 6.69 (1H, d, $J = 8.5$ Hz, H-5), and 6.93 (1H, dd, $J = 1.5, 8.5$ Hz, H-6). An AABB system was also evident, with peaks at δ 7.15 (2H, d, $J = 8.5$ Hz, H-2', H-6') and 6.65 (1H, d, $J = 8.5$ Hz, H-3', H-5') indicating the presence of a 1,3,4-trisubstituted aromatic system and a *p*-substituted aromatic ring, respectively. Two doublets proton signals at δ 7.34 (1H, d, $J = 15.5$ Hz, H-7) and 6.32 (1H, d, $J = 15.5$ Hz, H-8) indicated the presence of a *trans*-substituted double bond. Additional signals indicated the presence of an oxygenated methine proton at δ 4.75–4.77 (1H, m, H-7'), methylene protons at δ 3.46 (1H, dd, $J = 7.0, 13.5$ Hz, H-8'a) and 3.63 (1H, dd, $J = 5.5, 13.5$ Hz, H-8'b), a methoxyl at δ 3.79 (3H, s), in addition to a glucosyl anomeric proton at 4.40 (1H, d, $J = 7.5$ Hz, H-1''). ^{13}C -NMR and DEPT spectra of **1** revealed 24 carbon signals corresponding to 12 aromatic carbon atoms (for two aromatic rings), one oxymethine group at δ 81.8 (C-7'), one methylene group at 47.7 (C-8'), one double bond at δ 142.4 (C-7) and 118.6 (C-8), one carbonyl at δ 169.3 (C-9), one methoxyl group at δ 56.4 (3-OCH₃), and six carbon atoms belonging to a glucosyl moiety at δ 62.6 to δ 78.1 (Table 1). These spectroscopic data suggest that **1**




Figure 1. Selected HMBC and COSY correlations of **1**.

contains a feruloyl group and a 2-amino ethanoyl side chain, indicating that the main skeleton is cinnamic acid amide with a glycoside moiety. Acid hydrolysis of **1** in 1 N methanolic hydrochloric acid (HCl), together with the observed coupling constant of the anomeric proton ($J = 7.6$ Hz), confirmed the presence of D-(+)-glucose. Further confirmation was provided by direct comparisons with a reference sample in co-spotted (co)-TLC and GC analyses (Supplementary data). COSY, HSQC, and HMBC spectra confirmed the planar structure of **1** (Figure 1). The COSY spectrum revealed couplings between the oxymethine proton H-7' and the two nitrogenated methylene protons H-8', and between the two olefinic protons H-7 and H-8. The HMBC spectrum of **1** showed long-range correlations between H-7 and the carbonyl carbon C-9 and methine carbons C-2 and C-6, indicating the presence of a feruloyl group. Interestingly, long-range correlations between H-8' protons and the carbonyl carbon C-9 and oxygenated methine carbon C-7' confirmed the presence of a 2-hydroxy-2-(4-hydroxyphenyl) ethyl amine group (octopamine) linked to C-9 of the ferulic unit. A single methoxyl group at C-3 was evidenced by an HMBC correlation between δ_{H} 3.79 and δ_{C} 150.9 (C-3). HMBC correlations between δ_{H} 4.40 (H-1'') and δ_{C} 81.8 indicated that the glucopyranosyl unit was linked to the oxygen atom at C-7'. In addition, the optical rotation value of aglycon of **1** was determined as negative ($\alpha_{\text{D}} -3.0$), indicating the absolute configuration of S at the chiral center C-7' [17]. Based on all of the above evidence, the structure of **1** was characterized as physalucoside A.

NO is a key mediator of inflammatory responses and pathogenesis. The inhibition of NO by each of the isolated compounds (**1-11**) was evaluated in RAW246.7 cells by measuring NO production after LPS stimulation (1 $\mu\text{g/ml}$). The data in Table 2 show that physagulin B (**2**), (2*S*,22*R*)-15 α -acetoxy-5 α -chloro-6 β ,14 β -dihydroxy-1-oxowitha-2,24-dienonide (**3**), physalin B (**5**), and physagunin R (**7**) strongly inhibited NO production, with IC_{50} values less than 1.0 μM , followed by physalin F (**4**, IC_{50} 1.06 \pm 0.68 μM) and physalin G (**6**, IC_{50} 3.74 \pm 0.29 μM). The new compound, physalucoside A, also exhibited significant inhibitory activity, with an IC_{50} value of 2.69 \pm 0.17 μM , and the isolated flavonoid glucosides showed weak inhibition, with IC_{50} values greater than 30 μM . The positive control, cardamomin, showed anti-NO production activity, with an IC_{50} value of 1.17 \pm 0.10 μM . These results indicate that withanolides play an active role in the anti-inflammatory activity of *P. angulata*.

Interestingly, all of the withanolide compounds (**1-7**) were good inhibitors of NO production. iNOS and COX-2 are two main targets typically evaluated in anti-inflammation studies [18]. Physalin F (**4**) and physalin B (**5**) were selected for use in our subsequent experiments. RAW 264.7 cells were pretreated with the indicated concentrations of physalin F (**4**) and physalin G (**5**) for 2 h and then incubated with LPS

Table 2. Inhibition of NO production in macrophage RAW264.7 cells by 1–11.

Compounds	IC ₅₀ (μM) ^a
1	2.69 ± 0.17
2	0.24 ± 0.09
3	0.68 ± 0.02
4	1.06 ± 0.68
5	0.28 ± 0.10
6	3.74 ± 0.29
7	0.57 ± 0.18
8	12.5 ± 1.70
9	> 30
10	> 30
11	> 30
Cardamonin ^b	1.17 ± 0.10

^aThe inhibitory effects are represented as giving 50% inhibition (IC₅₀) relative to the vehicle control. The values are expressed as the means ± S.D. of three individual experiments.

^bPositive control for NO production.




Figure 2. Effect of physalins F (A) and physalins B (B) on LPS-induced iNOS and COX-2 expressions in RAW 264.7 macrophages. Expressions of iNOS and COX-2 proteins were determined by Western blot analysis and tubulin was chosen as positive control.

(1 μg/ml) for 24 h. Equal amounts of total protein were subjected to SDS-PAGE, and the levels of iNOS and COX-2 proteins were determined by Western blot analyses. The data in Figure 2 show that iNOS and COX-2 protein and mRNA expression were almost undetectable in unstimulated (no LPS activation) RAW 264.7 cells. However, after LPS treatment, the protein levels of iNOS and COX-2 increased markedly. Pretreating the cells with physalins F (4, 0.1–3.0 μM) and physalins G (5, 0.01–0.3 μM) attenuated LPS-induced iNOS and COX-2 protein production in a concentration-dependent manner. These data suggest that both of these compounds, along with the other withanolides, may downregulate LPS-induced iNOS and COX-2 expression at the transcription level. These results are consistent with those of previous studies [19,20] and provide evidence for the anti-inflammatory properties of *P. angulata*. Furthermore, experiments to confirm the anti-inflammation mechanism of these compounds are now in process.

The potentially cytotoxic activities of compounds 1–11 were investigated using three human cancer cell lines: A-549 (human lung carcinoma cells), HeLa (human cervical cancer cells), and Panc-1 (human pancreatic cancer cells). Compounds 3, 4, 5, and 6 exhibited particularly strong cytotoxic activities against A-549 cancer cell lines, with IC₅₀ values of 1.03 ± 0.09, 0.68 ± 0.05, 0.95 ± 0.04, and 6.88 ± 2.41 μM, respectively. These results are comparable with that for the positive control, etoposide (IC₅₀ 2.68 ± 0.89 μM) (Table 3). Therefore, the withanolide constituents (3–6) of *P. angulata* are potentially candidate anticancer therapeutic agents.

Table 3. Cytotoxic effect of selected compounds.

Compounds	IC ₅₀ (μM)		
	A-549	Hela	Panc-1
3	1.03 ± 0.09	29.89 ± 1.15	11.53 ± 0.36
4	0.68 ± 0.05	0.23 ± 0.03	>30
5	0.95 ± 0.04	13.84 ± 1.27	12.77 ± 1.07
6	6.88 ± 2.41	>30	>30
Etoposide ^a	2.68 ± 0.89	3.29 ± 0.05	0.08 ± 0.11

^aPositive control. The values are presented as the means ± S.D (n = 3).

Natural products are a consistent source of active pharmacological compounds. Previously, withanolides isolated from *P. angulata* exhibited remarkable anti-inflammatory, antinociceptive, and anti-cancer activities [21,22]. In this research, 11 compounds (**1–11**), including the new compound physalucoside A, were isolated from a methanol extract of *P. angulata* via combined column chromatography. Compounds **3**, **4**, **5**, and **6** exhibited significant anti-inflammatory and cytotoxic effects. Among these, compounds **5** and **6** exhibited iNOS and COX-2 expression in Western blot analyses. Our results indicate that the withanolides in *P. angulata* may potentially be used to treat inflammation, cancer, and other related diseases.

3. Experimental

3.1. General experimental procedures

The optical rotation values were recorded with a JASCO P-1020 polarimeter (JASCO, Oklahoma, OK, US). FT-IR spectra were performed on a Bruker TENSOR 37 FT-IR spectrometer (Bruker, Billerica, MS, USA). 1D and 2D NMR spectra were carried out on a Bruker Avance III 500 spectrometers (MA, USA) with TMS as the internal standard. HR-ESI-MS results were afforded by Agilent 6530 Accurate-Mass Q-TOF LC/MS system (Agilent, Santa Clara, CA, USA). Silica gel (Kieselgel 60, 70-230, and 230-400 mesh, Merck, Darmstadt, Germany), YMC*GEL (ODS-A, 12 nm S-150 μm, YMC Co., Ltd., Kyoto, Japan), and Sephadex LH-20 (Sigma-Aldrich, MO, USA), and Diaion HP-20 (Supelco, PA, USA) were chosen for the column chromatography by similarly described [23]. All solvents were supplied by SK chemical Company, Korea. Sigma-Aldrich provided the chemical reagents, and tubulin antibodies while iNOS, and COX-2 were afforded from Cell Signaling Technology (Beverly, MA, USA).

3.2. Plant material

The plant material of *Physalis angulata* was obtained from Thai Binh province, Vietnam, in June 2018. Dr. Tran Thi Phuong Anh and Prof. Young Ho Kim taxonomically identified the plant species. A voucher specimen (QTB 16 2018) was stored at the herbarium of the Natural Product Laboratory, Chungnam National University.

3.3. Extraction and isolation

The dried and powdered form of whole plants of *P. angulata* (2.0 kg) were extracted by methanol at 50 °C using ultrasonic for three times (4.0 L each). After removal of

the solvent, the methanol extract (90 g) was suspended in distilled water (1.5 L) and successively partitioned with dichloromethane and ethyl acetate (three times, 1.5 L each) to give corresponding soluble extracts, dichloromethane (PAD, 24.5 g), ethyl acetate (PAE, 4.6 g), and water-soluble layers (PAW). The PAD fraction was then subjected through a silica gel column and eluted with dichloromethane/methanol (0%, 25%, 50%, 75%, and 100% volume of methanol, each 1.5 L, stepwise) to give five fractions PAD1 - PAD5. Fraction PAD3 (1.8 g) was chromatographed on a silica gel column, eluting with dichloromethane/methanol (15:1) to give five sub-fractions PAD3.1-PDA3.5. Fraction PAD3.2 was purified on an RP-18 reverse phase column and eluted with methanol/water (1:1) to yield compound **6** (5.3 mg). Fraction PAD3.3 was further separated on a silica gel column, eluting with dichloromethane/acetone (15:1 and 15:2) to obtain compounds **1** (5.6 mg) and **2** (6.5 mg). Sub-fraction PAD3.5 was further chromatographed on a silica gel column, eluting with dichloromethane/methanol (10:1, and 10:2), and then further purified on a silica gel column, eluting with dichloromethane/acetone (8:1) to give compounds **4** (12.0 mg) and **5** (10.7 mg). Fraction PAD5 (4.5 g) was separated on an RP18 reversed phase column using methanol/water (2:1) to give three smaller fractions (PAD5.1 - PAD5.3). Fraction PAD5.2 was purified on a silica gel column using dichloromethane/acetone (6:1 and 3:1) to yield **3** (7.0 mg) and **7** (4.5 mg). The water-soluble layers were passed through the Diaion column HP-20, washed with distilled water, then eluted with increasing volume of methanol in water (25%, 50%, 75%, and 100% of methanol) to obtain four fractions PAW1 - PAW4. The fraction PAW2 (3.8 g) was chromatographed on a silica gel column, eluting with dichloromethane/methanol/water (3:1:0.01) to yield two sub-fractions PAW 2.1 and PAW2.2. The sub-fractions PAW2.2 (0.8 g) was continuously separated on an RP18 reversed phase column using methanol/water (1:2); then further purified on a Sephadex LH-20 column, eluting with methanol/water (3:1) to yield compound **8** (10 mg). Fraction PAW4 (3.1 g) was subjected to a silica gel column and eluted with dichloromethane/methanol/water (2:1:0.01) to give two smaller fractions PAW4.1 and PAW4.2. Fraction PAW4.1 (1.1 g) was passed through an RP18 reversed phase column using acetone/water (1:2); and then purified on a silica gel column, eluting with ethyl acetate/methanol/water (3:1:0.05) to give compounds **9** (6.2 mg) and **10** (7.5 mg). Fraction PAW4.2 (0.6 g) was purified on a silica gel column using dichloromethane/methanol/water (2:1:0.01) as eluent to afford compound **11** (10.1 mg).

3.3.1. Physalucoside A (1)

White amorphous powder; $[\alpha]_D^{20} -0.080$ (c 0.25, CHCl_3); IR (KBr) ν_{\max} 3380, 1635, 1605, and 1520 cm^{-1} ; ^1H (500 MHz in CD_3OD) and ^{13}C -NMR (125 MHz in CD_3OD) spectral data, see Table 1; HR-ESI-MS: m/z 492.1838 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{24}\text{H}_{30}\text{NO}_{10}$, 492.1870).

3.4. Anti-inflammatory effects

The anti-inflammatory assay was carried out by previously reported protocol with small modification [24]. RAW264.7 cells were obtained from American Type Culture Collection (ATCC, TIB-71, Rockville, MD, USA) and cultured in DMEM

supplemented with 10% fetal bovine serum (FBS, 16000-044, Gibco, Grand Island, NY, USA) and 100 U/ml penicillin-streptomycin (Gibco) at 37 °C in incubator containing 5% CO₂. Cells were plated at 5×10^4 cells/well in 96-well culture plates and then were incubated with compounds for 1 h before LPS (0.1 µg/ml) stimulation for 18 h. Cell supernatant (100 µl) was mixed with an equal amount of Griess reagent consisting of 1% sulfanilamide (Sigma, St. Louis, MO, USA) and 0.1% N-(1-naphthyl)ethylenediamine (Sigma) in 5% phosphoric acid. Its absorbance was measured at 550 nm using a microplate reader (Varioskan LUX, Thermo Fisher Scientific Inc., Waltham, MA, USA).

3.5. Cytotoxic activity

Cytotoxic activity was performed using MTT assay by previously reported method [25]. Cell viability was evaluated by the MTT assay. Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) was added to the cells for 2 h. The supernatant was removed and then the MTT formazan crystals were dissolved in dimethyl sulfoxide (DMSO, Sigma). Absorbance was recorded at 570 nm using a microplate reader (Thermo Fisher Scientific Inc.).

3.6. Western blotting analysis

According to our previous protocol with minor modification, Western blot analysis was carried out to identify iNOS, and COX-2 protein expression in the RAW264.7 cells [18,23]. Briefly, RAW264.7 cells (2×10^6 cells/well) were treated with LPS (0.1 µg/ml) for 16 h after pre-incubated with compounds **4** and **5** for 1 h. The cells lysate was extracted using Cell Lysis Buffer (Cell Signaling Technology) according to the manufacturer's protocol.

3.7. Statistical analysis

The results were calculated by using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA). The significant difference between compounds treated group and LPS alone group was evaluated by one-way analysis of variance (ANOVA) followed by Dunnett's test ($*p < 0.05$).

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This study was financially supported by Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 104.01-2016.26.

ORCID

Young Ho Kim  <http://orcid.org/0000-0002-7441-9459>

References

- [1] H.J. Yoon, M.E. Moon, H.S. Park, S.Y. Im, and Y.H. Kim, *Biochem. Biophys. Res. Commun.* **358**, 954 (2007).
- [2] X. Zhang, and D. Mosser, *J. Pathol.* **214**, 161 (2008).
- [3] M.B. Soares, M.C. Bellintani, I.M. Ribeiro, T.C. Tomassini, and R.R. dos Santos, *Eur. J. Pharmacol.* **459**, 107 (2003).
- [4] H.L. Tuan Anh, D.T. Thao, D.T. Dung, P.V. Kiem, T.H. Quang, P.T. Hai Yen, D.T. Tuan, P.V. Cuong, L.C. Viet Cuong, and T.M. Hung, *Phytochem. Lett.* **27**, 193 (2018).
- [5] E. Rengifo-Salgado, and G. Vargas-Arana, *B. Latinoam. Caribe PL.* **12**, 431 (2013).
- [6] M.S. Sá, M.N. de Menezes, A.U. Krettli, I.M. Ribeiro, T.C.B. Tomassini, R. Ribeiro dos Santos, W.F. de Azevedo, and M.B.P. Soares, *J. Nat. Prod.* **74**, 2269 (2011).
- [7] C.P. Sun, M.B. Oppong, F. Zhao, L.X. Chen, and F. Qiu, *Org. Biomol. Chem.* **15**, 8700 (2017).
- [8] MdS. Lima, AnF. Evangelista, GGaLd Santos, I.M. Ribeiro, T.C.B. Tomassini, M.B. Pereira Soares, and C.F. Villarreal, *J. Nat. Prod.* **77**, 2397 (2014).
- [9] E.M. Reyes-Reyes, Z. Jin, A.J. Vaisberg, G.B. Hammond, and P.J. Bates, *J. Nat. Prod.* **76**, 2 (2013).
- [10] S.Y. Wu, Y.L. Leu, Y.L. Chang, T.S. Wu, P.C. Kuo, Y.R. Liao, C.M. Teng, and S.L. Pan, *Plos One.* **7**, e40727 (2012).
- [11] C.S. Meira, E.T. Guimarães, J.A.F. dos Santos, D.R.M. Moreira, R.C. Nogueira, T.C.B. Tomassini, I.M. Ribeiro, C.V.C. de Souza, R.R. dos Santos, and M.B.P. Soares, *Phytomedicine* **22**, 969 (2015).
- [12] H.C. Chiang, S.M. Jaw, and P.M. Chen, *Anticancer Res.* **12**, 1155 (1992).
- [13] Y.Z. Li, Y.M. Pan, X.Y. Huang, and H.S. Wang, *Helv. Chim. Acta.* **91**, 2284 (2008).
- [14] N. Pinto, T. Morais, K. Carvalho, C. Silva, G.M. Andrade, G.A.C. Brito, M. Veras, O. Pessoa, V. Rao, and F. Santos, *Phytomedicine* **17**, 740 (2010).
- [15] Y.W. Yang, L. Yang, C. Zhang, C.Y. Gao, T. Ma, and L.Y. Kong, *RSC Adv.* **7**, 12793 (2017).
- [16] M. Wolbiś, *Phytochemistry* **28**, 2187 (1989).
- [17] M. DellaGreca, L. Previtera, R. Purcaro, and A. Zarrelli, *Tetrahedron* **62**, 2877 (2006).
- [18] L.B. Vinh, Y. Lee, Y.K. Han, J.S. Kang, J.U. Park, Y.R. Kim, S.Y. Yang, and Y.H. Kim, *Bioorg. Med. Chem. Lett.* **27**, 5149 (2017).
- [19] Y.J. Yang, L. Yi, Q. Wang, B.B. Xie, Y. Dong, and C.W. Sha, *Immunopharmacol. Immunotoxicol.* **39**, 74 (2017).
- [20] C.-P. Sun, C.-Y. Qiu, T. Yuan, X.-F. Nie, H.-X. Sun, Q. Zhang, H.-X. Li, L.-Q. Ding, F. Zhao, L.-X. Chen, and F. Qiu, *J. Nat. Prod.* **79**, 1586 (2016).
- [21] C.P. Sun, C.Y. Qiu, F. Zhao, N. Kang, L.X. Chen, and F. Qiu, *Sci. Rep.* **7**, 4057 (2017).
- [22] B. Dong, L. An, X. Yang, X. Zhang, J. Zhang, M. Tuerhong, D.-Q. Jin, Y. Ohizumi, D. Lee, J. Xu, and Y. Guo, *Bioorg. Chem.* **87**, 585 (2019).
- [23] L.B. Vinh, H.J. Jang, N.V. Phong, K.W. Cho, S.S. Park, J.S. Kang, Y.H. Kim, and S.Y. Yang, *Bioorg. Med. Chem. Lett.* **29**, 965 (2019).
- [24] C. Wang, H.J. Jang, Y. Han, X. Su, S. Lee, M.C. Rho, H.-S. Wang, S. Yang, and Y. Kim, *Molecules* **23**, 1445 (2018).
- [25] L.B. Vinh, N.T.M. Nguyet, S.Y. Yang, J.H. Kim, N.V. Thanh, N.X. Cuong, N.H. Nam, C.V. Minh, I. Hwang, and Y.H. Kim, *Nat. Prod. Res.* **33**, 628 (2019).